Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
Is a
Allocation Type
Randomized
0
Health Conditions in Trial
Intervention Model
Parallel Assignment
0
Interventional Trial Phase
Phase 2
0
Interventional Trial Purpose
Treatment
0
Last Updated
July 20, 2009
0
Masking Type
Double
0
Trial Recruitment Size
150
0
Trial Sponsor
Clinical Trial Start Date
2003
0
Study Completion Date
2006
0
Clinical Trial Study Type
Interventional
0
NCT Number
Official Name
A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Study of Intravenous Daclizumab in Patients With Moderate-to-severe Ulcerative Colitis
0
Official Website
Find more entities like Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.